Chiome Bioscience Inc. (JP:4583) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chiome Bioscience Inc. has entered into an exclusive licensing agreement with Asahi Kasei Pharma for the development and commercialization of its anti-CX3CR1 antibody, PFKR. The deal includes an upfront payment of ¥200 million to Chiome and potential milestone payments up to ¥24.8 billion, along with royalties based on future sales.
For further insights into JP:4583 stock, check out TipRanks’ Stock Analysis page.